SYK vs UTHR
Stryker Corporation vs United Therapeutics — AI-powered side-by-side comparison
SYK
Stryker Corporation
59
Buy
VS
UTHR
United Therapeutics
70
Buy
| Metric | SYK | UTHR |
|---|
| AI Score |
59
|
70
|
| Price |
$331.47
|
$516.60
|
| P/E Ratio |
33.98×
|
17.15×
|
| ROE |
14.5%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
65.2%
|
86.1%
|
| Debt / Equity |
0.62×
|
0.00×
|
| Dividend Yield |
1.1%
|
0.0%
|
| RSI (14) |
44.6
|
51.0
|
| Beta |
0.771
|
0.564
|
| Expected Upside |
+13.1%
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for SYK versus UTHR.
UTHR leads by 11 points.
UTHR scores 70/100 (Buy) versus SYK at 59/100 (Buy).
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
UTHR Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 11.7% downside vs 0.1% upside.